Completed

NCT Number: NCT02517892

A Prospective Trial to Study the Evolution of Clonal Architecture of Tumors From Patients Treated With Molecular Targeted Agents

This is a prospective study to identify molecular mechanisms of acquired resistance to targeted therapies in patients with unresectable or metastatic cancer.

This is a protocol to study clinical characteristics and biopsy tissue of patients with oncogene-driven cancer who have had previous clinical response to targeted therapy and subsequently experience progression of disease. The tissues and other specimens will be used to carry out laboratory studies to explore the molecular basis of acquired resistance to targeted therapies.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Metastatic Oncogen-driven Cancer

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Gustave Roussy Cancer Campus Grand Paris

Villejuif, Val De Marne, 94805, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients diagnosed with confirmed cancer and who fulfill the following eligibility criteria will be considered eligible for this study:

Patient affiliated to a social security regimen
Patients scheduled to receive anticancer agents or currently receiving anticancer agents
Tumor lesion accessible to core biopsies (malignant effusions can represent an alternative)
Patient who is fully informed, able to comply with the protocol and who signed the informed consent.
Availability of initial tumor material (ideally frozen, or non-Bouin fixed paraffin embedded material) acquired before exposure to the targeted therapy Note: Patients may have received other treatments since treatment with targeted therapies including radiation or chemotherapy, before undergoing the study biopsy.

Exclusion criteria

Coagulation abnormality prohibiting a biopsy

Treatment and study plan

Biopsy

Procedure

Primary outcomes

Type and frequency of molecular alterations in resistant tumors using whole exome sequencing

Time frame: 30 days after inclusion

Sponsors and collaborators

Lead sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Other

Registry information

Acronym: MATCH-R

Important dates

Study start: 2014
Primary completion: 2025
Study completion: 2025
First posted: Aug 7, 2015
Registry last updated: Jun 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.